340 related articles for article (PubMed ID: 24627343)
1. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
2. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Abbas A; Nehme E; Fakih M
Anticancer Res; 2011 Dec; 31(12):4637-40. PubMed ID: 22199342
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
4. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
6. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
9. Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer.
Hoch MA; Cousins K; Nartey R; Riley K; Hartranft M
J Oncol Pharm Pract; 2018 Oct; 24(7):553-554. PubMed ID: 28764598
[TBL] [Abstract][Full Text] [Related]
10. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer.
Forastiere AA; Urba SG
Semin Oncol; 1995 Jun; 22(3 Suppl 6):24-7. PubMed ID: 7597431
[TBL] [Abstract][Full Text] [Related]
11. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
Crehange G; Bosset M; Lorchel F; Dumas JL; Buffet-Miny J; Puyraveau M; Mercier M; Bosset JF
Dis Colon Rectum; 2007 Jan; 50(1):43-9. PubMed ID: 17089083
[TBL] [Abstract][Full Text] [Related]
12. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.
Darnton SJ; Archer VR; Stocken DD; Mulholland PJ; Casson AG; Ferry DR
J Clin Oncol; 2003 Nov; 21(21):4009-15. PubMed ID: 14581424
[TBL] [Abstract][Full Text] [Related]
13. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
[TBL] [Abstract][Full Text] [Related]
14. Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
Hancock SB; Krempl GA; Canfield V; Bogardus C; Kojouri K; Kaneaster SK; Medina JE
Laryngoscope; 2008 Aug; 118(8):1357-61. PubMed ID: 18528311
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor inhibition in metastatic anal cancer.
Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM
Semin Oncol; 2000 Feb; 27(1 Suppl 1):36-40. PubMed ID: 10697043
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
Kobayashi K; Matsuyama H; Shimizu K; Fujii N; Inoue R; Yamamoto Y; Matsumoto H; Nagao K
Jpn J Clin Oncol; 2016 Aug; 46(8):775-80. PubMed ID: 27272172
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of advanced anal cancer].
Norum J; Wist E
Nord Med; 1992; 107(8-9):227-8. PubMed ID: 1408730
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
20. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
